Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.342 EUR | -2.84% | -2.29% | -14.71% |
Apr. 30 | Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 11 | Biofrontera Files Prospectus for Potential Secondary Stock Offerings | MT |
Sales 2021 | 28.79M 31M | Sales 2022 | 25.74M 27.72M | Capitalization | 97.31M 105M |
---|---|---|---|---|---|
Net income 2021 | 38M 40.92M | Net income 2022 | -44M -47.39M | EV / Sales 2021 | 2.79 x |
Net cash position 2021 | 3.61M 3.89M | Net cash position 2022 | 4.88M 5.25M | EV / Sales 2022 | 3.59 x |
P/E ratio 2021 |
2.18
x | P/E ratio 2022 |
-1.98
x | Employees | 92 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 32.4% |
Latest transcript on Biofrontera AG
1 day | -2.84% | ||
1 week | -2.29% | ||
Current month | -2.29% | ||
1 month | +0.59% | ||
3 months | -23.15% | ||
6 months | -33.20% | ||
Current year | -14.71% |
Managers | Title | Age | Since |
---|---|---|---|
Director of Finance/CFO | 55 | 22-09-11 | |
Anke zur Muehlen
IRO | Public Communications Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 63 | 21-12-13 | |
Director/Board Member | - | 21-12-13 | |
Heikki Lanckriet
BRD | Director/Board Member | 46 | 21-12-13 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 0.342 | -2.84% | 12,599 |
24-05-09 | 0.352 | +0.57% | 2,000 |
24-05-08 | 0.35 | 0.00% | 6,003 |
24-05-07 | 0.35 | 0.00% | 650 |
24-05-06 | 0.35 | 0.00% | 650 |
Delayed Quote Xetra, May 10, 2024 at 11:36 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.71% | 23.5M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- B8F Stock